ZA99912B - Live vaccine for human immunodeficiency virus. - Google Patents

Live vaccine for human immunodeficiency virus.

Info

Publication number
ZA99912B
ZA99912B ZA9900912A ZA99912A ZA99912B ZA 99912 B ZA99912 B ZA 99912B ZA 9900912 A ZA9900912 A ZA 9900912A ZA 99912 A ZA99912 A ZA 99912A ZA 99912 B ZA99912 B ZA 99912B
Authority
ZA
South Africa
Prior art keywords
hiv
mice
live vaccine
vaccine
proteins
Prior art date
Application number
ZA9900912A
Other languages
English (en)
Inventor
Mary Susan Burnett
George Barry Kitto
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of ZA99912B publication Critical patent/ZA99912B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
ZA9900912A 1998-02-06 1999-02-05 Live vaccine for human immunodeficiency virus. ZA99912B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7394398P 1998-02-06 1998-02-06

Publications (1)

Publication Number Publication Date
ZA99912B true ZA99912B (en) 2000-08-07

Family

ID=22116747

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900912A ZA99912B (en) 1998-02-06 1999-02-05 Live vaccine for human immunodeficiency virus.

Country Status (13)

Country Link
EP (1) EP1061950B1 (xx)
JP (1) JP2002502827A (xx)
KR (1) KR20010040618A (xx)
CN (1) CN1216640C (xx)
AT (1) ATE287727T1 (xx)
AU (1) AU744730B2 (xx)
CA (1) CA2320489A1 (xx)
DE (1) DE69923439D1 (xx)
IL (1) IL137680A0 (xx)
NZ (1) NZ506093A (xx)
RU (1) RU2223784C2 (xx)
WO (1) WO1999039735A1 (xx)
ZA (1) ZA99912B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AU2001286405B2 (en) * 2000-07-31 2007-05-10 Yale University Innate immune system-directed vaccines
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
CN106237316A (zh) 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
CN101195823B (zh) * 2007-11-20 2010-06-02 华东理工大学 细菌表面展示系统、方法及应用
CN109207417A (zh) * 2018-09-19 2019-01-15 湖北省农业科学院畜牧兽医研究所 鸡白痢-j亚群禽白血病双重平板凝集抗原及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
AU9179891A (en) * 1990-12-19 1992-07-22 Epitope, Inc. Hiv reverse transcriptase vaccine
AU3958895A (en) * 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes

Also Published As

Publication number Publication date
DE69923439D1 (de) 2005-03-03
JP2002502827A (ja) 2002-01-29
WO1999039735A1 (en) 1999-08-12
CN1216640C (zh) 2005-08-31
EP1061950A1 (en) 2000-12-27
EP1061950B1 (en) 2005-01-26
WO1999039735A9 (en) 2000-01-27
RU2223784C2 (ru) 2004-02-20
CN1290175A (zh) 2001-04-04
KR20010040618A (ko) 2001-05-15
AU3180199A (en) 1999-08-23
NZ506093A (en) 2003-08-29
ATE287727T1 (de) 2005-02-15
AU744730B2 (en) 2002-02-28
CA2320489A1 (en) 1999-08-12
EP1061950A4 (en) 2001-12-05
IL137680A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
Mayr et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs
Shata et al. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T cells and antiviral protective immunity
Barnett et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope
Buge et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
Shibata et al. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
Hammond et al. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
Lin et al. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut
Sedlik et al. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses
Premenko-Lanier et al. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate
Buge et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251
Verschoor et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance
Maeto et al. Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity
Guo et al. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles
Yao et al. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity
IL137680A0 (en) Live vaccine for human immunodeficiency virus
Zhou et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIVmac251
Schnell Viral vectors as potential HIV-1 vaccines
Yoshino et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates
Kumar et al. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
Koopman et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian–human immunodeficiency virus viraemia with protein/DNA combination
Gotch Cross-clade T cell recognition of HIV. 1
Anderson et al. Overcoming original (antigenic) sin
Shacklett et al. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251
Schultz et al. Primate models for AIDS vaccines